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Abstract 
The terms “licensed”, “unlicensed”, and “off-label”, often used in relation to marketing and 
prescribing medicinal products, may confuse UK prescribers. 
 To market a medicinal product in the UK requires a Marketing Authorisation (“product 
licence”) for specified indications under specified conditions, regulated by the Medicines and 
Healthcare products Regulatory Agency (MHRA). The Marketing Authorisation includes the 
product’s agreed terms of use (the “label”), described in the Summary of Product 
Characteristics (SmPC). Prescribing a licensed product outside those terms is called “off-
label” prescribing. Products for which no-one holds a UK Marketing Authorisation are 
unlicensed. 
 Prescribers can prescribe authorised products according to the conditions described in the 
SmPC (“on-label”) or outside those conditions (“off-label”). They can also prescribe 
unauthorised products, unlicensed in the UK, if they are licensed elsewhere or if they have 
been manufactured in the UK by a licensed manufacturer as a “special”. 
 The complexities of this system can be understood by considering the status of the 
manufacturer of the product, the company that markets it (which may or may not be the 
same), the product itself, and its modes of use, and by emphasizing the word “authorised”. 
 If a Marketing Authorisation is granted to the supplier of a product, it will specify the 
authorised modes of use; the product will be prescribable as authorised (i.e. “on-label”) or in 
other modes of use, which will all be off-label. Unlicensed products with no authorised 
modes of use can be regarded as “unauthorised products”. All “specials” can be regarded as 
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Introduction 
The terms “unlicensed” and “off-label” in relation to the marketing and prescribing of 
medicinal products are widely used but are potentially confusing and may be misunderstood. 
Here we discuss definitions and offer clarifications. We shall deal only with legislation in the 
UK. 
 We exclude from this discussion medical devices and advanced therapy medicinal 
products (ATMPs, products used for gene therapy or somatic cell therapy or tissue engineered 
products) [1], for which there are special exemptions. 
Regulation of medicines in the UK 
The history of medicines regulation in the UK [2] is briefly described in Appendix 1. 
 In the UK there is a Licensing Authority responsible for granting, renewing, varying, 
suspending, and revoking licences for medicinal products. This Authority, created by the 
1968 Medicines Act, is defined as “the Minister of Health [in England & Wales], the 
Secretary of State concerned with health in Scotland and the Minister of Health and Social 
Services for Northern Ireland.” 
 Currently, the Licensing Authority is advised by the Commission on Human Medicines 
(CHM) through the Medicines and Healthcare products Regulatory Agency (MHRA), which 
issues all authorisations for medicinal products for human use and licences for manufacturers 
and wholesalers of such products across the UK. 
 Medicines regulation controls the ways in which medicinal products are marketed, not the 
ways in which they are prescribed. Prescribers are regulated by other bodies, for example the 
General Medical Council (GMC) for doctors, the General Pharmaceutical Council (GPhC) for 
pharmacists, and the Nursing & Midwifery Council (NMC) for nurses and midwives. 
 The 1968 Medicines Act introduced the UK system whereby applicants are granted 
licences (now known as Marketing Authorisations, colloquially known as product licences), 
permitting them to market medicinal products for specified indications under specified 
conditions. The current UK law is contained in the Human Medicines Regulations 2012, a 
UK Statutory Instrument that is legislation secondary to the Medicines Act and not itself a 
full Act [3]. The regulation of medicinal products for human use in the UK is also currently 
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subject to EU law, as outlined in Directive 2001/83/EC on the Community code relating to 
medicinal products for human use [4], which is discussed in relevant parts of the text below 
and also in Appendices 3 and 4. The MHRA is only one regulatory agency that contributes to 
the deliberations of the European Medicines Agency (EMA), and in some cases it has no 
major input. Even when a national licence is granted in the UK, regulation is still subject to 
EU law. At the time of writing it is not clear how the MHRA will make regulatory 
recommendations if and when the UK leaves the European Union. In the first instance, all EU 
law will be incorporated into UK statutes, but changes may subsequently be made. It is 
unlikely that UK regulation will revert to the position that existed before the formation of the 
EMA (see Appendix 1), but neither is it clear to what extent the MHRA will be willing to 
accept EMA decisions into which it has had no input, rather than setting up the complex 
apparatus, under amended legislation, whereby it could make its own recommendations to the 
Licensing Authority. Any changes that are made may take many years to effect. 
Definitions 
Here we explain a range of terms that are pertinent to the use of unlicensed medicines and the 
off-label use of licensed medicines. The relevant definitions are listed in Table 1. 
 
Table 1. Definitions discussed in this paper 
 
Note on nomenclature 
A Marketing Authorisation is defined below. Those who hold Marketing Authorisations in 
the UK are known as Marketing Authorisation Holders (MAHs). Separate licences are issued 
to manufacturers and wholesalers. A Marketing Authorisation Holder may also hold a 
separate manufacturing licence. 
 Because a Marketing Authorisation is granted to the MAH, not to the product, terms such 
as “licensed drug”, “licensed medicine”, and “licensed product”, commonly used colloquially, 
are not strictly accurate. Neither the drug itself nor the medicinal product in which it is 
formulated is licensed. It is the MAH who is licensed, i.e. given permission, by the Licensing 
Authority to market the product. Nevertheless, we shall use the terms “licensed product” and 
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“unlicensed product” here, since they are commonly used and afford appropriate shorthand. 
Thus, when we say “licensed product” we mean a product whose MAH has been granted a 
licence to market it for specified indications, and when we say “unlicensed product” we refer 
to a product for which no UK licence has been issued for any indication. 
Marketing authorisation and licensed and unlicensed medicinal products 
The WHO has defined a marketing authorisation as “an official document issued by the 
competent drug regulatory authority for the purpose of marketing or free distribution of a 
product after evaluation for safety, efficacy and quality” [5]. Although UK legislation has not 
explicitly defined the terms “product licence” or “marketing authorisation”, Section 7 of the 
1968 Medicines Act stipulates that, except in accordance with a product licence, “no person 
shall, in the course of a business carried on by him … 
(a) sell, supply or export any medicinal product, or 
(b) procure the sale, supply or exportation of any medicinal product, or 
(c) procure the manufacture or assembly of any medicinal product for sale, supply or 
exportation.” 
 This text implies that a marketing authorisation (product licence) can be defined as 
“permission granted to a marketing authorisation holder to sell, supply, or export, procure the 
sale, supply or exportation, or procure the manufacture or assembly for sale, supply or 
exportation of a specified medicinal product”. 
 There are two main routes for authorising medicines in the European Union (EU), a 
centralised route and a national route [6]. For centralised authorisation, a single application is 
submitted to the EMA. The licence, if granted, allows the MAH to market the medicine and 
make it available in all Member States and in the European Economic Area (EEA) countries 
(Iceland, Liechtenstein, and Norway). In addition, each EU Member State has its own 
national authorisation procedures, under which most medicines in the UK have been 
authorised, either because they were authorised before the EMA was established or because 
they did not come within the scope of the centralised procedure. However, an MAH who 
holds a licence, whether via the centralized or national route, is not obliged to market the 
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product in a country in which the product is licensed. If a product is licensed but not marketed 
it may, if prescribed, be imported from a country in which it is marketed. 
 An “unlicensed product” can be defined, based on the definition in the Unlicensed 
Medicinal Products for Human Use (Transmissible Spongiform Encephalopathies) (Safety) 
Regulations 2003 [7], as “a medicinal product for human use [with some exceptions, such as 
herbal products], in respect of which no marketing authorisation has been granted by the 
[national] licensing authority or by the European Medicines Agency”. 
 A medicinal product is defined as: 
“(a) any substance or combination of substances presented as having properties of 
preventing or treating disease in human beings; or 
(b) any substance or combination of substances that may be used by or administered to 
human beings with a view to 
(i) restoring, correcting or modifying a physiological function by exerting a 
pharmacological, immunological or metabolic action, or 
(ii) making a medical diagnosis.” 
 A medicinal product is authorised if there is in force for the product 
(a) a marketing authorisation; 
(b) a certificate of registration as a homoeopathic medicinal product [8]; 
(c) a traditional herbal registration; or 
(d) an Article 126a authorisation. 
 An Article 126a authorisation, under EU law, is one that can be issued to license a product 
whose use is justified for public health reasons and that has been imported from another 
Member State in the European Union where it has been authorised. For example, over 1600 
products have been licensed in Malta using this method [9]. At the time of writing it is not 
clear what will happen to this part of the definition if and when the UK leaves the European 
Union. 
 Any medicinal product for which a UK marketing authorisation has not been granted is an 
unlicensed product in the UK, even if it is licensed elsewhere. This is made explicit in 
Section 7 of the 1968 Act, which stipulates that “[n]o person shall import any medicinal 
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product except in accordance with a product licence”. Importation from non-EU states is 
covered in the 2012 Human Medicines Regulations. 
 Pharmaceutical modification of a licensed product can result in an unlicensed product. For 
example, bevacizumab is licensed for the treatment of metastatic colorectal cancer. If an 
undiluted solution of bevacizumab were used for intravitreous injection to treat age-related 
macular degeneration that would be using it off-label (see below). If, on the other hand, a 
solution was, say, diluted before use or divided into several aliquots, the secondary 
formulations would be regarded as being unlicensed [10,11,12]. How much pharmaceutical 
modification results in an unlicensed product is unclear. 
 The licensing system in the UK is intended to protect patients from the use of medicines 
with a poor benefit to harm balance, based on quality, efficacy, and safety. However, when a 
medicine has been licensed, it is prescribers who assess the benefit to harm balance and make 
decisions about whether that medicine should be prescribed, guided by factors such as those 
shown in Figure 1, which deal with the patient, the illness, the benefits, and the harms. The 
benefit to harm balance is most favourable when (a) the patient has little susceptibility to the 
potential harms (b) the disease is serious and severe, (c) there is substantial and well-
established efficacy, and (d) harms are well defined, unlikely, and trivial. This is especially 
important when the prescriber strays from the authorised modes of use. 
 
Figure 1. Four factors that influence the benefit to harm balance of drug therapy: features of 
the patient, features of the illness, the evidence of benefit, and adverse effects or reactions 
 
Label and labelling 
The term “label”, now widely used, originated in US legislation in 1938, when the Food, 
Drug and Cosmetic Act defined a label as “a display of written, printed, or graphic matter 
upon the immediate container of any article; and a requirement … that any word, statement, 
or other information appear[ing] on the label shall not be considered to be complied with 
unless such word, statement, or other information also appears on the outside container or 
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wrapper, if any there be, of the retail package of such article, or is easily legible through the 
outside container or wrapper.” 
 “Labelling” was defined in the 1938 Act as “all labels and other written, printed, or 
graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying 
such article.” Similarly, a drug label is described in The Human Medicines Regulations 2012 
as “a notice describing or otherwise relating to the contents”. 
 The term “label” is now used to mean not merely the “written, printed, or graphic matter” 
that accompanies the formulation, but the informative content of such matter, which in the 
UK is contained in the Summary of Product Characteristics (SmPC), previously called the 
Product Data Sheet. The SmPC is a legal document, approved as part of the marketing 
authorisation of each medicine, whose contents, as currently prescribed by EU law [13], are 
listed in Appendix 2. 
 SmPCs can vary markedly in describing the same medicine formulated by different 
manufacturers. As an example, each of six formulations of bendroflumethiazide, described in 
five SmPCs currently listed in the Electronic Medicines Compendium [14], constitutes a 
separate medicinal product, each with its own product licence number. The SmPCs for these 
different formulations differ in ways that are illustrated in Table 2. 
 
Table 2. An example of differences in UK SmPCs of products containing the same active 
ingredient, bendroflumethiazide, marketed in the same strengths by different manufacturers 
 
Off-label prescribing 
To recap: the Marketing Authorisation (product licence) of an approved medicinal product is 
granted to the Market Authorisation Holder. The product is then colloquially referred to as a 
“licensed product”. The product’s “approved uses” are the modes of use listed in Section 4 
(“Clinical Particulars”) of the SmPC (“the label”), which accompanies the licence. 
 If a licensed product is prescribed for use in a way that differs from the authorised ways 
described in the label, it is said to be prescribed “off-label”. In other words, off-label 
prescribing is the prescribing of a licensed product for use in an unauthorised way, which is 
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any way that differs from the ways specified in the SmPC. This is not the same as prescribing 
an unlicensed product. Table 3 lists different types of off-label and unlicensed prescribing; 
some are less hazardous than others, and the degree of hazard varies in different 
circumstances. 
 
Table 3. Types of off-label and unlicensed prescribing 
 
 The licensing restrictions stipulated in the 1968 Medicines Act and the 2012 Regulations 
relate to marketing and specify sale, supply, export, and import. They do not relate to 
prescribing. For example, a registered medical practitioner with a licence to practise granted 
by the GMC has a right to prescribe. 
 
Regulatory guidance 
The two main UK regulatory bodies that issue guidance about the prescribing of medicinal 
products are the GMC and the MHRA. 
 The GMC issued guidance in 2006 [15], revised in 2008 [16], in which it listed the 
precautions that prescribers should taken when writing prescriptions for all medicines, and 
specifically listing the different precautions required when prescribing unlicensed medicines 
and, separately, licensed medicines off-label. 
 However, in 2013 [17] the GMC, in its document “Good practice in prescribing and 
managing medicines and devices (2013)”, revised its guidance, conflating in Paragragh 67 the 
two categories of unlicensed medicines and licensed medicines that are used outside the terms 
of their UK licence (i.e. used off-label), applying the term “unlicensed medicines” to cover 
both, thus: 
“The term ‘unlicensed medicine’ is used to describe medicines that are used outside the 
terms of their UK licence or which have no licence for use in the UK.” 
The GMC supported this change from its previous guidance by citing the MHRA publication 
The supply of unlicensed medicinal products (“specials”), MHRA Guidance Note 14. 
However, the MHRA’s Guidance makes it clear that the term “unlicensed medicine” 
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specifically describes medicines that have no UK licence. When a medicine is “used outside 
the terms of [the] UK licence” that has been granted to its manufacturer, such use is off-label, 
not unlicensed, as the earlier GMC guidance made clear. Subsequent paragraphs in this 
section of the GMC's 2013 document (paragraphs 68–70) use the term “unlicensed” 
apparently to mean either “off-label” or “unlicensed and/or off-label” (see also below). Given 
this, it is hard to interpret this section of the GMC’s document. 
 We also note that in November 2015 the GMC offered a further elaboration [18]: 
“For clarity, in GMC guidance the term ‘unlicensed medicines’ refers to both medicines 
with no UK licence, and those being used outside of the terms of their licence (commonly 
referred to as ‘off-label’). Although there are of course differences between medicines 
which do not hold any UK licence and those used outside of the terms of their licence – 
our guidance is the same for both circumstances which is why they are grouped together in 
this context.” 
 Perhaps surprisingly, the GMC also implies that the duties of prescribers are the same 
when they prescribe licensed medicines, whether within or outside the terms of their licence, 
or unlicensed medicines, stating that “Importantly, prescribing unlicensed medicines will not 
put your registration at risk any more than other areas of practice covered by our guidance”. 
 We find nothing in the MHRA’s Guidance Note 14 to support the GMC’s use of the term 
“unlicensed” to encompass licensed medicines prescribed outside the terms of the licence (i.e. 
off-label). Indeed, the MHRA’s note clearly differentiates between “unlicensed” and “off-
label” and sets out their different uses in both Section 2.4 and at greater length in Section 2 of 
Appendix 2 in the document [19], which reads: 
“1. An unlicensed product should not be used where a product available and licensed 
within the UK could be used to meet the patient’s special need. 
“2. Although MHRA does not recommend “off label” (outside of the licensed indications) 
use of products, if the UK licensed product can meet the clinical need, even “off-
label”, it should be used instead of an unlicensed product. Licensed products available 
in the UK have been assessed for quality safety and efficacy. If used “off-label” some 
of this assessment may not apply, but much will still be valid. This is better than the 
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use of an un-assessed, unlicensed product. The fact that the intended use is outside of 
the licensed indications is therefore not a reason to use an unlicensed product. It 
should be understood that the prescriber’s responsibility and potential liability are 
increased when prescribing off-label. 
“3. If the UK product cannot meet the special need, then another (imported) medicinal 
product should be considered, which is licensed in the country of origin. 
“4. If none of these options will suffice, then a completely unlicensed product may have 
to be used, for example, UK manufactured “specials”, which are made in GMP [Good 
Manufacturing Practice] inspected facilities, but which are otherwise un-assessed 
(GMP inspection of “specials” manufacturers is not product specific). There may also 
be other products available which are unlicensed in the country of origin. 
“5. The least acceptable products are those that are unlicensed in the country of origin, 
and which are not classed as medicines in the country of origin (but are in the UK). 
For example, the use of products from countries where they are classed as 
supplements, not pharmaceuticals, and may not be made to expected standards of 
pharmaceutical GMP. These should be avoided whenever possible.” 
The text of this appendix clearly distinguishes the use of unlicensed products from the off-
label use of licensed products outside their licensed (i.e. approved) indications as stated in the 
label. 
 In contrast, the GMC’s 2013 guidance dichotomises products as licensed and unlicensed, 
and does not mention off-label use: 
“68. You should usually prescribe licensed medicines in accordance with the terms of their 
licence. However, you may prescribe unlicensed medicines where, on the basis of an 
assessment of the individual patient, you conclude, for medical reasons, that it is necessary 
to do so to meet the specific needs of the patient. 
“69. Prescribing unlicensed medicines may be necessary where: 
a. There is no suitably licensed medicine that will meet the patient’s need. 
... 
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b. Or where a suitably licensed medicine that would meet the patient’s need is not 
available.” 
 The Chairman of the GMC stated in April 2015 [20] that the GMC’s guidance “is based on 
current European law. The key judgment was European Commission v Republic of Poland 
(C-185/10) in 2012. This made clear that it was unlawful to prescribe an unlicensed medicine 
(medicines which have no licence for use in the UK or are used outside the terms of their 
licence) on grounds of cost when there was a licensed product available.” However, we 
believe that this reference to the cited case confuses marketing and prescribing, as Evans has 
suggested [21]. 
 The text of the Judgment of the Court (Third Chamber) in the case of the European 
Commission versus the Republic of Poland [22; Appendix 3] made it clear that the case dealt, 
not with prescribing, but with authorisation to market a medicinal product. It was specifically 
about the importation of a medicinal product that had “the same active substances, the same 
dosage and the same form” as other licensed products, but was cheaper, without the need for 
national authorisation, where Article 4 of the [Polish] Law on Medicinal Products conflicted 
with Article 6(1) of Directive 2001/83/EC. 
 
Providing medicines for “special needs” 
It is not illegal in the UK for a registered prescriber to prescribe an unlicensed product or a 
licensed product off-label. Unlicensed medicines can be supplied by so-called “special order” 
manufacturers, paradoxically under licence from the MHRA, obviating the need for a 
marketing authorisation. The relevant details about such “specials” are given in Appendix 4. 
 Although the prescription of an unlicensed product is restricted to specified circumstances, 
the restrictions do not apply to off-label prescription. This is why it is important that the 
definitions of “unlicensed” and “off-label” should be clear and properly understood. 
 
An operational description 
We believe that the confusion that can arise from the use of the terms “licensed”, 
“unlicensed”, and “off-label” can be mitigated by recognizing that there are several 
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components of the processes of authorization, manufacture, marketing, and prescribing of 
medicinal products, as shown in Figure 2. The key word is “authorised”. 
 When a product has been developed, a Marketing Authorisation may or may not be issued 
to a relevant applicant. A Marketing Authorisation Holder (MAH) holds an authorisation to 
market an authorised medicinal product, the term that is used in the 2012 Human Medicines 
Regulations to describe products for which authorizations have been issued. The modes of 
use of authorised medicinal products, as described in the SmPC, include the indications, 
contraindications, dosages, routes of administration, and requirements for monitoring. They 
are similarly authorised by agreement between the MHRA and the MAH. We use the term 
“modes of use” rather than “uses”, since the latter could be misinterpreted as being restricted 
to indications. Manufacturers, who are often the MAHs, are also authorised. Thus: 
 Authorised medicinal products with authorised modes of use are prescribable (dark green 
boxes in Figure 2). 
 If any mode of use is not part of the marketing authorisation, an authorised medicinal 
product may nevertheless also be prescribed, but in that case its use will be off-label (light 
green boxes in Figure 2). 
 Products that are unlicensed in the UK, “unauthorised medicinal products”, have by 
definition no authorised modes of use; such products can be imported and prescribed if 
they have been authorised elsewhere (rose boxes in Figure 2). 
 Otherwise unauthorised products are prescribable as “specials” under the current 
regulations, if manufactured by a licensed “specials” manufacturer (red boxes in Figure 2). 
 Compassionate use (lavender box) allows the use of unauthorised medicinal products, 
under strict conditions, so that products in development can be given to patients who have 
a disease with no satisfactory authorised therapies and who cannot enter clinical trials [23]. 
 The MHRA has set out a preferred order for prescribing products of different status (see 
items a–d in Appendix 4 and the bottom line in Figure 2). 
 
Figure 2. How authorised and unauthorised products are used and prescribed; the categories 
a–d correspond to those in Appendix 4; *the MAH and the licensed manufacturer may or may 
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Medicines legislation is designed to ensure that only products that have been assessed by a 
regulatory agency, and are of acceptable quality of manufacture, efficacy in the proposed 
indications, and safety, can be sold, supplied, or exported. It does not directly apply to the 
prescriber. Nevertheless, guidance from the MHRA emphasises the need for care when 
prescribers stray from the authorised modes of use. 
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Appendix 1: A brief history of medicines regulation in the UK 
Informal licensing of medicines and of individual practitioners to prescribe goes back 
hundreds of years [24]. In 1540 Henry VIII, who had founded the Royal College of Physicians 
in 1518, promulgated The Pharmacy Wares, Drugs, and Stuffs Act, empowering the 
physicians to inspect apothecaries’ wares and destroy them if defective. This control 
continued even after 1617, when The Worshipful Society of the Art and Mistery of 
Apothecaries was founded, but by the start of the 18
th
 century the power of the physicians 
over the apothecaries had waned, and the rights of apothecaries to visit the sick and prescribe 
medicines, which they were already doing, with little control from the physicians, were 
established [25]. 
 The establishment of the Food and Drugs Administration (FDA), following the 1906 Pure 
Food and Drugs Act [26], and later the 1938 Food, Drug and Cosmetic Act, marked the start 
of modern medicines regulation in the USA. In the UK, the 1917 Venereal Disease Act 
imposed the earliest constraint on the marketing of medicines, stipulating that “a person shall 
 This article is protected by copyright. All rights reserved. 
not hold out or recommend to the public, by any notice or advertisement, or by any written or 
printed papers or handbills, or by any label or words written or printed, affixed to or delivered 
with, any packet, box, bottle, phial, …any [formulation] to be used … for the prevention, 
cure, or relief of any venereal disease” [27]. The 1939 Cancer Act included a similar 
prohibition [28]. 
 Following the thalidomide affair [29,30,31], the Standing Medical Advisory Committee of 
the Ministry of Health, chaired by Lord Cohen of Birkenhead, advised the establishment of 
the Committee on Safety of Drugs (CSD) in 1963 [32], whose main functions were pre-
marketing scrutiny of new drugs, before they were subjected to clinical trials, and post-
marketing surveillance to monitor adverse drug reactions, document them, and issue 
appropriate warnings. A report produced by the CSD led to the 1968 Medicines Act, which 
created a Medicines Commission to advise a Licensing Authority. The Authority was defined 
as a body of ministers, namely “the Minister of Health [in England & Wales], the Secretary of 
State concerned with health in Scotland and the Minister of Health and Social Services for 
Northern Ireland”. The Medicines Commission established the Committee on Safety of 
Medicines (CSM) under Section 4 of the Act, and recommendations from these two bodies 
were transmitted to the Licensing Authority initially by the Medicines Division within the 
Ministry (later Department) of Health and then by a secretariat called the Medicines Control 
Agency (MCA) after its establishment in 1989 [33]. 
 In 2003 the MCA and the Medical Devices Agency (MDA) were merged to form the 
Medicines and Healthcare products Regulatory Agency (MHRA), with later incorporation of 
the National Institute for Biological Standards and Control (NIBSC). The Medicines 
Commission and the CSM have since been jointly replaced by the Commission on Human 
Medicines (CHM), which now advises the Licensing Authority about drug licensing through 
the MHRA, which issues all authorisations for medicinal products for human use and licences 
for manufacturers and wholesalers of such products across the UK. The Licensing Authority 
is responsible for the grant, renewal, variation, suspension, and revocation of licences and 
certificates. 
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 The 1968 Med 
icines Act introduced the UK system whereby applicants are granted licences (now known as 
Marketing Authorisations, colloquially known as product licences), permitting them to 
market medicinal products for specified indications under specified conditions. Matters 
relating to prescribing were later covered by The Prescription Only Medicines (Human Use) 
Order 1997 [34], which partially repealed the 1968 Act. That Order was later mostly revoked 
by the Human Medicines Regulations 2012 [35], which consolidated the law contained in 
previous instruments and is a UK Statutory Instrument, legislation secondary to the 
Medicines Act and not itself a full Act. 
 
Appendix 2. The headings under which information about a medicinal 
product must be given in the Summary of Product Characteristics by EU 
law 
1. Name of the medicinal product 
2. Qualitative and quantitative composition 
3. Pharmaceutical form 
4. Clinical particulars 
4.1 Therapeutic indications 
4.2 Posology and method of administration 
4.3 Contraindications 
4.4 Special warnings and precautions for 
use 
4.5 Interaction with other medicinal 
products and other forms of interaction 
4.6 Fertility, pregnancy and lactation 
4.7 Effects on ability to drive and use 
machines 
4.8 Undesirable effects 
4.9 Overdose 
5. Pharmacological properties 
5.1 Pharmacodynamic properties 
5.2 Pharmacokinetic properties 
5.3 Preclinical safety data 
6. Pharmaceutical particulars 
6.1 List of excipients 
6.2 Incompatibilities 
6.3 Shelf life 
6.4 Special precautions for storage 
6.5 Nature and contents of container 
6.6 Special precautions for disposal 
and other handling 
7. Marketing authorisation holder 
8. Marketing authorisation number(s) 
9. Date of first authorisation/renewal of 
the authorisation 
10. Date of revision of the text 
 
Appendix 3. The text of the Judgment of the Court (Third Chamber) in the 
case of the European Commission versus the Republic of Poland 
“By its application, the European Commission asks the Court to declare that, by adopting and 
maintaining in force Article 4 of the Law on Medicinal Products (Prawo farmaceutyczne) of 6 
September 2001, as amended by the Law of 30 March 2007 (Dz. U. No 75, heading 492) 
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(‘the Law on Medicinal Products’), inasmuch as that statutory provision dispenses with the 
requirement for a marketing authorisation for medicinal products from abroad which have the 
same active substances, the same dosage and the same form as those having obtained a 
marketing authorisation in Poland, on condition that, in particular, the price of those imported 
medicinal products is competitive in relation to the price of products having obtained such 
authorisation, the Republic of Poland has failed to fulfil its obligations under Article 6 of 
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on 
the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as 
amended by Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 
13 November 2007 (OJ 2007 L 324, p. 121) (‘Directive 2001/83’).” 
 The first subparagraph of Article 6 of Directive 2001/83/EC [4] reads as follows: 
“No medicinal product may be placed on the market of a Member State unless a marketing 
authorisation has been issued by the competent authorities of that Member State in 
accordance with this Directive or an authorisation has been granted in accordance with 
Regulation (EC) No 726/2004, read in conjunction with Regulation (EC) No 1901/2006 of 
the European Parliament and of the Council of 12 December 2006 on medicinal products for 
paediatric use (2) and Regulation (EC) No 1394/2007.” 
 The next subparagraph extends an initial marketing authorisation granted in accordance 
with the previous subparagraph to “any additional strengths, pharmaceutical forms, 
administration routes, [or] presentations”. 
 The final judgment of the court, stated in paragraph 52, was as follows: 
“Consequently, it must be held that, by adopting and maintaining in force Article 4 of the 
Law on Medicinal Products, inasmuch as that statutory provision dispenses with the 
requirement for a marketing authorisation for medicinal products from abroad which have the 
same active substances, the same dosage and the same form as those having obtained a 
marketing authorisation in Poland, on condition that, in particular, the price of those imported 
medicinal products is competitive in relation to the price of products having obtained such 
authorisation, the Republic of Poland has failed to fulfil its obligations under Article 6 of 
Directive 2001/83.” 
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Appendix 4. Providing medicines for “special needs” 
It is not illegal in the UK for a registered prescriber to prescribe an unlicensed product or a 
licensed product off-label. Unlicensed medicines can be supplied by so-called “special order” 
manufacturers, who are licensed by the MHRA, obviating the need for a marketing 
authorisation. 
 Section 2.6 of Guidance Note 14 specifies the conditions under which a manufacturer may 
supply a “special”: 
 However, Appendix 2 in the MHRA’s Guidance Note 14 (quoted in full above) advises on 
priorities in choosing medicinal products to prescribe, as follows, in each case assuming that 
the earlier choices are not available: 
(a) use a licensed product within the terms of its licence (i.e. the label); 
(b) use a licensed product off-label; 
(c) use an imported product that has a licence elsewhere; 
(d) use a product that is not licensed anywhere, but which has been manufactured in the UK 
as a "special". 
 [We have not included here the final piece of guidance relating to products that are not 
classed as medicines in the country of origin, but are so classed in the UK, since such 
instances are rare.] 
 This guidance is of practical importance to prescribers, because their responsibility and 
potential liability in law may be greater when they prescribe a medicine other than in case (a) 
above [36]. 
 Section 2.6 of Guidance Note 14 specifies the conditions under which a manufacturer may 
supply a “special”: 
 there is an unsolicited order; 
 the product is manufactured and assembled in accordance with the specification of a 
person who is a doctor, dentist, nurse independent prescriber, pharmacist independent 
prescriber or supplementary prescriber registered in the UK; 
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 the product is for use by a patient for whose treatment that person is directly 
responsible in order to fulfill the special needs of that patient; and 
 the product is manufactured and supplied under specific conditions [as specified in 
Appendix 1 of the guidance]. 
 Under Article 5(1) of Directive 2001/83/EC the requirement to have a national marketing 
authorisation can be waived in the case of “special needs”, when the doctor considers that the 
state of health of an individual patient requires that a medicinal product be administered for 
which there is no authorised equivalent on the national market or which is unavailable on that 
market. The Guidance Note (Section 2.2) specifies that “An unlicensed medicinal product 
should not be supplied where an equivalent licensed medicinal product can meet the special 
needs of the patient. ... Examples of ‘special needs’ include an intolerance or allergy to a 
particular ingredient, or an inability to ingest solid oral dosage forms.” Furthermore, Section 
2.3 specifies that “The requirement for a “special need” relates to the special clinical needs of 
the individual patient. It does not include reasons of cost, convenience or operational needs.” 
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Figure 1. Four factors that influence the benefit to harm balance of drug therapy: features of 
the patient, features of the illness, the evidence of benefit, and adverse effects or reactions 
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Figure 2. How authorised and unauthorised products are used and prescribed; the categories 
a–d correspond to those in Appendix 4; *the MAH and the licensed manufacturer may or may 
not be the same company and may or may not be the company that develops the drug; PoM = 
prescription-only medicine 
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Table 1. Definitions discussed in this paper 
Term Definition 
Medicinal product (a) any substance or combination of substances presented as 
having properties of preventing or treating disease in human 
beings; or 
(b) any substance or combination of substances that may be used 
by or administered to human beings with a view to 
(i) restoring, correcting or modifying a physiological function 
by exerting a pharmacological, immunological or 
metabolic action, or 
(ii) making a medical diagnosis 
Marketing authorisation Permission granted to a Marketing Authorisation Holder legally to 
sell, supply, or export, procure the sale, supply or exportation, or 
procure the manufacture or assembly for sale, supply or 




A medicinal product, marketed by a specified company, for which 
there is in force 
(a) a marketing authorisation; 
(b) a certificate of registration as a homoeopathic medicinal 
product; 
(c) a traditional herbal registration; or 
(d) an Article 126a authorisation 
Summary of Product 
Characteristics (SmPC) 
That part of the Marketing Authorisation that contains essential 
information for the use of a medicine, including pharmacological 
properties, authorised indications, qualitative and quantitative 
information on benefits and harms, information for individualised 
care, and pharmaceutical information 
Article 126a 
authorisation 
An EU authorisation that can be issued to license a product whose 
use is justified for public health reasons and that has been 
imported from another Member State in the European Union 
Authorised modes of 
use 
The ways of using the medicinal product as specified in the  
Summary of Product Characteristics (see Appendix 2) 
Unauthorised product 
(“unlicensed product”) 
A medicinal product for human use in respect of which no 
marketing authorisation has been granted by a relevant licensing 
authority 
Label A notice describing or otherwise relating to the contents of a 
medicinal product; the agreed terms of the Marketing 
Authorisation granted in respect of a medicinal product and set out 
in the Summary of Product Characteristics 
Off-label prescribing Prescribing of an authorised product for use in a way that is not 
described in the Summary of Product Characteristics 
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Table 2. An example of differences in UK SmPCs of products containing the same active ingredient, bendroflumethiazide, marketed in the same 




Sovereign Medical (brand name 
Aprinox; one SmPC for two products) 
Wockhardt (two SmPCs, one for 
each strength) 
Actavis (two SmPCs, one for each strength) 
Strength 2.5 and 5 mg 2.5 and 5 mg 2.5 and 5 mg 
Stated indications  Oedema [conditions not specified] 
 Hypertension 
 Suppression of lactation 
 Essential hypertension 
 Oedema [conditions specified] 
 Reduction of fluid retention by diuresis; 
oedema [conditions specified] 
 Antihypertensive agent 
Stated 
contraindications 
 Known hypersensitivity to thiazides 
 Refractory hypokalaemia, 
hyponatraemia, hypercalcaemia 
 Severe renal and hepatic impairment 
 Symptomatic hyperuricaemia 
 Addison's disease 
 Hypercalcaemia 
 Severe renal insufficiency or 
anuria 
 Severe hepatic impairment (risk of 
precipitation of encephalopathy) 
 Addison's disease 
 [Administration] with lithium 
carbonate 
 Hypersensitivity to thiazides and any other 
ingredient 
 Patients with rare hereditary problems of 
galactose intolerance, the Lapp lactase 
deficiency or glucose-galactose malabsorption* 
 Severe renal or hepatic insufficiency 
 Hypercalcaemia; refractory hypokalaemia; 
hyponatraemia; symptomatic hyperuricaemia 




 Renal function should be continuously 
[sic] monitored 
 Regular ongoing monitoring and 
blood tests are to be performed in 
elderly patients and patients who are 
on long term treatment with 
bendroflumethiazide 
 Elderly: electrolyte balance and 
renal function should be carefully 
monitored 
 Serum electrolyte and blood urea 
levels should be carefully 
monitored in seriously ill patients 
 Blood glucose concentrations 
should be monitored in patients 
taking antidiabetics 
 Renal function should be monitored 
 Elderly patients and those on long term 
treatment need regular blood tests to monitor 
electrolyte levels 
 Serum calcium levels should be monitored to 
ensure that they do not become excessive 
 Patients [taking digoxin] should be monitored 
for signs of digoxin intoxication, especially 
arrhythmias 
 Plasma lithium concentrations must be 
monitored when these drugs are given 
concurrently 
 Patients [taking carbenoxolone and 
bendroflumethiazide] should be monitored and 
given potassium supplements when required 
*All three products contain lactose as an excipient 
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Table 3. Types of off-label and unlicensed prescribing 
Category Examples 
Types of off-label prescribing in which the medicine is not approved for the intended indication 
1. The branded formulation is not 
approved for the intended indication, but 
other branded formulations of the same 
medicine are so approved 
Inderal–propranolol is not approved for treatment of 
infantile haemangiomas, but Hemangiol–propranolol is so 
approved 
2. The medicine is not approved in any 
formulation for the intended indication, 
but other medicines of the same 
pharmacological class, which might be 
expected to be efficacious, are so approved 
Licensed formulations of bisoprolol and celiprolol do not 
include the treatment of migraine among their approved 
indications, but licensed formulations of propranolol and 
oxprenolol do 
3. The medicine is not approved in any 
formulation for the intended indication, 
and no other medicine of the same 
pharmacological class is so approved 
either 
Amitriptyline is used to treat neuropathic pain and is 
effective, although it is not licensed in any formulation for 
this indication, and neither is any other tricyclic 
antidepressant 
4. The medicine is approved for an 
indication and can be used in cases where 
the indication is assumed but not known 
Use of ampicillin, indicated for the treatment of a wide 
range of bacterial infections caused by ampicillin-sensitive 
organisms, to treat infections whose cause is not known or 
when infecting bacteria are not known to be sensitive 
Types of off-label prescribing in which the medicine is approved for the intended indication but not in 
other respects, e.g. population, dose, or frequency of administration 
5. For an unapproved age group Many examples of prescribing for children, when the 
prescribed drug is approved for the relevant indication in 
adults but not children 
6. In an unapproved dosage regimen Use of an oral contraceptive in twice the recommended dose 
to obviate reduced efficacy due to a drug-drug interaction 
7. By an unapproved route of 
administration 
Giving bevacizumab intravitreously for age-related macular 
degeneration (AMD); this is also an example of an off-label 
indication, since the approved indications for bevacizumab 
do not include AMD 
8. With omission of therapy with a drug 
mandated in the SmPC for co-
administration 
Prescribing infliximab without methotrexate in rheumatoid 
arthritis as a therapeutic trial in a patient who cannot tolerate 
methotrexate 
9. When monitoring that is mandated by 
the SmPC is omitted 
Failing to monitor serum sodium concentrations in patients 
taking low-dose diuretics for hypertension, taking into 
account evidence that it is of no therapeutic benefit to do so 
Unlicensed products that can be prescribed but need to be imported or provided as specials 
Glycopyrronium bromide (available in the 
UK for injection) 
Glycopyrronium bromide 0.05% topical solution 
Hydroquinone (no licensed product 
marketed in the UK) 
Hydroquinone 4% cream 
Melatonin (available in the UK as a 
modified-release formulation) 
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